Clinical Trial Update: Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

View source ↗

Summary

An expanded access program update for axicabtagene ciloleucel (Yescarta) for patients with diffuse large B-cell lymphoma and follicular lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Yescarta (axicabtagene ciloleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Large B-cell Lymphoma, Follicular Lymphoma | Status: AVAILABLE